About Pharnext

Company Description

Our company

Pharnext is an advanced clinical-stage biopharmaceutical company developing novel therapeutics for neurodegenerative diseases with high unmet medical needs.

Our drug Candidates

Two drug candidates are currently in clinical development: PXT3003 for the treatment of Charcot-Marie-Tooth disease type 1A and PXT864 for Alzheimerโ€™s disease. Both of our lead assets originated from the Pleotherapy R&D approach.

Year founded

2007

Served area

Worldwide

Headcount

44

Headquarters

46 Rue Saint Lazare, 75009 Paris โ€“ France

Shareholder information

Shares outstanding

314,984,176

IPO

July 18, 2016

Stock exchange(s)

Euronext Paris

Contact

Newsletter

Subscribe to our newsletter and receive information about recent IPOs, news in the European capital market and more.